Company / R&D Expense
Perspective Therapeutics, Inc. R&D Expense History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$850.0K
FY2022
5-year range
$528.0K / $1.7M
FY2018-FY2022
Trend
-42.3%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $528,000 in FY2018 to $2M in FY2020.
Based on SEC 10-K filings.
$850,000 in FY2022 with a 5-year CAGR of +6.7%.
Declined from $2M to $850,000 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -4.1%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2022, r&d expense decreased 42.3% year-over-year.
- Peak r&d expense was recorded in FY2020.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $850.0K | -42.3% |
| FY2021 | $1.5M | -15.6% |
| FY2020 | $1.7M | +80.9% |
| FY2019 | $965.0K | +82.8% |
| FY2018 | $528.0K | -14.1% |
| FY2017 | $615.0K | -8.0% |
| FY2016 | $668.8K | +6.6% |
| FY2015 | $627.1K | +0.0% |
| FY2014 | $627.1K | -19.7% |
| FY2013 | $780.6K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026